Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety, Immune Function of Pirfenidone in the Treatment of Connetive Tissue Disease -Related Interstitial Lung Disease(CTD-LID)

NCT05505409 is registered in ClinicalTrials.gov with Qilu Hospital of Shandong University as lead sponsor.

NCT NCT05505409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05505409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety, Immune Function of Pirfenidone in the Treatment of Connetive Tissue Disease -Related Interstitial Lung Disease(CTD-LID)
Lead sponsor
Qilu Hospital of Shandong University
Phase
Phase 4
Overall status
Unknown status
Start date
June 22, 2022
Completion date
December 1, 2025
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

connective tissue diseases, interstitial lung disease, pirfenidone